Regentis Biomaterials Advances European Commercial Launch for GelrinC with Surgeon Training Program

Regentis Biomaterials Ltd. (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026, a critical step in the commercial rollout of GelrinC, its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant, starting at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.

The training initiative is a key component of Regentis’ European commercialization strategy. The company will establish a network of Centers of Excellence focused on surgeon education, clinical guidance, and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and expanding physician familiarity with the technology is expected to support adoption as the product enters broader clinical use.

GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. According to the company, the product aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is currently available.

Regentis Biomaterials is a regenerative medicine company focused on developing innovative tissue repair solutions. The Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue, including inflamed cartilage and bone. The company’s lead product, GelrinC, received CE Mark approval, allowing it to be marketed in Europe.

For more information, the full press release is available at https://ibn.fm/QOWWK. Updates on Regentis Biomaterials can also be found in the company’s newsroom at https://ibn.fm/RGNT.